The massive beat and strong cash position support the commercial launch of YARTEMLEA and pipeline development. Monitor upcoming EMA decision on YARTEMLEA in mid-2026 and future milestone payments from Novo Nordisk as key catalysts.
Price Chart
Executive Summary
Omeros reported a massive earnings beat for Q4 2025, driven by a $237.6M gain from the zaltenibart sale to Novo Nordisk and FDA approval of YARTEMLEA. The company turned profitable with GAAP net income of $86.5M ($1.22/share) versus a $31.4M loss in the prior year, while non-GAAP adjusted EPS hit $3.14, crushing consensus. Cash rose to $171.8M and debt was slashed by 47%.
Key Financial Metrics
Key Facts
- Net income for Q4 2025 was $86.5M ($1.22/share), compared to a net loss of $31.4M ($0.54/share) in Q4 2024
- Non-GAAP adjusted net income was $222.5M ($3.14/share), a 670.9% beat vs. consensus of $-0.55
- Recognized $237.6M in net proceeds from the sale of zaltenibart to Novo Nordisk
- FDA approved YARTEMLEA for TA-TMA, with commercial launch underway in January 2026
- Cash and short-term investments totaled $171.8M at year-end; debt reduced by $77.1M (47%) to $87.9M
- OMIDRIA royalties were $9.2M in Q4 2025, down from $10.1M in Q4 2024
Financial Impact
$237.6M one-time gain from asset sale, $133.4M non-GAAP annual adjusted net income, $171.8M cash on hand
Risk Factors
- Future earnings may decline as the $237.6M gain from the zaltenibart sale was non-recurring
- OMIDRIA royalties continue to trend downward, falling to $9.2M in Q4 from $10.1M in the prior year
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-010634 |
| Document: omer20251116_8k.htm | 0001437749-26-010634 |
| Document: 0001437749-26-010634-index-headers.html | 0001437749-26-010634 |
| Document: 0001437749-26-010634-index.html | 0001437749-26-010634 |
| Document: 0001437749-26-010634.txt | 0001437749-26-010634 |
| 8-K Data (Synthetic) | 0001437749-26-010634 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | Insider Cluster | $18.75 $19.04 | ▲ +1.55% | ▲ +1.44% | $18.30 (−2.40%) |
Aug 28, 2026 5w ago | Insider Cluster | $18.61 $19.43 | ▲ +4.41% | ▲ +4.15% | $18.30 (−1.67%) |
Aug 25, 2026 5w ago | Insider Cluster | $18.22 $20.13 | ▲ +10.48% | ▲ +10.26% | $18.30 (+0.44%) |
Aug 21, 2026 5w ago | Insider Cluster | $19.32 $21.05 | ▲ +8.95% | ▲ +7.64% | $18.30 (−5.28%) |
Jul 20, 2026 10w ago | 8-K | $9.53 $17.19 | ▲ +80.38% | ▲ +77.82% | $18.30 (+92.03%) |
Jul 6, 2026 12w ago | 8-K | $10.34 $11.84 | ▲ +14.51% | ▲ +15.07% | $18.30 (+76.98%) |
Jun 18, 2026 15w ago | 8-K | $10.28 $9.22 | ▼ −10.31% | ▼ −10.84% | $18.30 (+78.02%) |
Jun 11, 2026 16w ago | Institutional Cluster | $10.18 $10.27 | ▲ +0.88% | ▼ −1.01% | $18.30 (+79.76%) |
May 13, 2026 20w ago | 8-K | $13.28 $8.74 | ▼ −34.19% | ▼ −33.33% | $18.30 (+37.80%) |
Mar 31, 2026 26w ago | 8-K | $12.08 $14.56 | ▲ +20.53% | ▲ +10.81% | $18.30 (+51.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access